Daily Cosmetic Research Analysis
Three impactful cosmetic-dermatology studies stood out today: a large psychometric validation confirming convergent validity for key FACE-Q Aesthetics scales, a double-blind half-face clinical study showing that an ascorbyl glucoside–arginine complex improves solar lentigos over 24 weeks, and a retrospective cohort demonstrating the safety and efficacy of a 730-nm picosecond laser for ABNOM in Chinese patients. Together, they advance outcome measurement, pigmentation therapy, and device-based tr
Summary
Three impactful cosmetic-dermatology studies stood out today: a large psychometric validation confirming convergent validity for key FACE-Q Aesthetics scales, a double-blind half-face clinical study showing that an ascorbyl glucoside–arginine complex improves solar lentigos over 24 weeks, and a retrospective cohort demonstrating the safety and efficacy of a 730-nm picosecond laser for ABNOM in Chinese patients. Together, they advance outcome measurement, pigmentation therapy, and device-based treatment safety.
Research Themes
- Patient-reported outcome measures in aesthetic medicine
- Clinical treatment of hyperpigmentation
- Laser/device safety and efficacy in darker skin types
Selected Articles
1. Establishing Convergent Validity of the FACE-Q Aesthetics Module Scales.
In an online international cohort (n=1259), multiple FACE-Q Aesthetics appearance scales showed adequate convergent validity against MERZ patient-reported scales, whereas Face Overall and Cheeks did not. This supports the use of specific FACE-Q scales for evaluating outcomes of minimally invasive facial aesthetic treatments.
Impact: Validated patient-reported outcome measures underpin robust trials and comparative effectiveness research in aesthetics. These findings guide instrument selection and interpretation.
Clinical Implications: Use FACE-Q appearance scales with demonstrated convergent validity (e.g., lines, lower face/jawline, lips) for outcome assessment after minimally invasive facial procedures; interpret Face Overall and Cheeks scales with caution or seek additional validation.
Key Findings
- Online international sample of 1,259 adults undergoing minimally invasive facial aesthetics completed 11 FACE-Q and 12 MERZ scales.
- FACE-Q scales for lines (multiple facial regions), lower face/jawline, and lips showed adequate convergent validity with MERZ patient-reported scales.
- FACE-Q Face Overall and Cheeks did not reach predefined thresholds for convergent validity.
Methodological Strengths
- Large, international sample with a priori hypotheses for correlations
- Blinded, predefined thresholds for convergent validity against a comparator instrument
Limitations
- Online, self-selected cohort may introduce selection bias
- Cross-sectional design without clinical outcomes or longitudinal responsiveness
Future Directions: Prospective studies assessing responsiveness, minimal clinically important differences, and validation versus clinician/observer-rated outcomes across diverse populations.
BACKGROUND: FACE-Q Aesthetics scales can be used to assess patient-important outcomes following both surgical and nonsurgical facial cosmetic interventions. Convergent validity is the degree to which the scores of one measurement relate to another measuring a similar construct. OBJECTIVES: The aim of this study was to establish the convergent validity of 11 FACE-Q Aesthetics appearance scales vs the MERZ Aesthetics (Raleigh, NC) scales. METHODS: Data were collected from an online international sample of participants aged ≥20 years, who had presented to a dermatologist or plastic surgeon within the previous 12 months for a minimally invasive facial aesthetic treatment. Participants provided demographic and clinical data and completed 11 FACE-Q Aesthetics scales and 12 MERZ Aesthetics scales. Hypotheses regarding the strength of correlations between these scales were generated a priori. Adequate convergent validity was based on the percentage of correct hypotheses (>75%) and/or correlation ≥0.50 with an instrument measuring a similar construct. RESULTS: In total, 1259 participants were included in this survey. The mean [standard deviation] age of the participants was 42.6 [11.9] years old, and most were female (72.5%), Caucasian (76.9%), and living in the United States (49.9%) or the United Kingdom (42.9%). FACE-Q Lines Overall, Lower Face and Jawline, Appraisal of Lines-Forehead/Between Eyebrows/Crow's Feet/Lips/Nasolabial Folds/Marionette, and Lips scales demonstrated adequate convergent validity with patient-reported MERZ Aesthetics scales. The FACE-Q Face Overall and Cheeks scales did not show adequate convergent validity. CONCLUSIONS: This study provides evidence of convergent validity for FACE-Q Aesthetics appearance scales. Establishing the validity of these scales remains an iterative process and further studies comparing the FACE-Q to other related measurement tools are required to strengthen this evidence.
2. Treatment with Ascorbyl Glucoside-Arginine Complex Ameliorates Solar Lentigos.
In a double-blind half-face study of 27 Japanese women with solar lentigos, twice-daily application of a 28% AGAC lotion significantly improved pigmentation scores, increased lightness, and decreased melanin index at 12 and 24 weeks versus baseline and placebo. No hypopigmentation or safety issues were observed.
Impact: Provides controlled clinical evidence for a novel depigmenting complex in solar lentigos, a common cosmetic concern, with measurable benefits over 24 weeks.
Clinical Implications: AGAC may be considered as a non-hydroquinone option for solar lentigos, with objective improvements and a favorable safety profile; clinicians should confirm efficacy across skin types and combine with photoprotection.
Key Findings
- Double-blind half-face design with twice-daily application for 24 weeks in 27 Japanese women with solar lentigos.
- Significant reductions in pigmentation scores and melanin index and increases in lightness at 12 and 24 weeks versus baseline and placebo.
- No hypopigmentation or skin adverse events observed during the study.
Methodological Strengths
- Double-blind, within-subject half-face control design
- Objective instrumental measurements (colorimeter, Mexameter) over 24 weeks
Limitations
- Small sample size and single-ethnicity (Japanese females)
- Single concentration/formulation; histologic mechanisms not assessed
Future Directions: Larger multicenter RCTs across Fitzpatrick skin types, head-to-head comparisons with standard agents (e.g., hydroquinone), and mechanistic/biopsy studies.
Little is known about the anti-pigmenting effects of skin-whitening agents on solar lentigos (SLs). To characterize the anti-pigmenting effects of a newly designed derivative ascorbyl glucoside-arginine complex (AGAC) on SLs, lotions with or without 28% AGAC were applied twice daily for 24 weeks in a double-blind half-face study of 27 Japanese females with SLs. The pigmentation scores and skin colors of previously selected SLs on the right and left sides of the faces of the subjects were evaluated using a photo-scale, a color difference meter and a Mexameter. Treatment with the test lotion elicited a significant decrease in pigmentation scores at 24 weeks compared to week 0, with a significant decrease in pigmentation scores at 24 weeks compared to the placebo lotion. In the test lotion-treated SLs, the lightness (L) and melanin index (MI) values that reflect the pigmentation level significantly increased and decreased, respectively, at 12 and 24 weeks of treatment compared to week 0. Comparisons of increased L values or decreased MI values between the test and placebo lotion-treated SLs demonstrated that the test lotion-treated SLs had significantly higher increased L or decreased MI values than the placebo lotion-treated SLs both at 12 and 24 weeks of treatment. The sum of our results strongly indicates that AGAC is distinctly effective in ameliorating the hyperpigmentation levels of SLs at a level visibly recognizable by the subjects, without any hypo-pigmenting effects or skin problems.
3. Efficacy and Safety of 730-nm Picosecond Laser for the Treatment of Acquired Bilateral Nevus of Ota-like Macules.
In 72 Chinese patients with ABNOM (Fitzpatrick III–IV), a 730-nm picosecond laser achieved a 75% overall effectiveness after an average of 2.4 sessions, with progressive improvement across sessions, no hypopigmentation, and a 5.6% PIH rate. Blinded photo assessments support safety and efficacy in darker skin types.
Impact: Supports the use of a specific picosecond wavelength for ABNOM in Fitzpatrick III–IV skin with low dyspigmentation risk, informing device selection and counseling.
Clinical Implications: The 730-nm picosecond laser can be considered for ABNOM in darker skin types with careful parameter selection; monitor for PIH (~5.6%) and plan for multiple sessions.
Key Findings
- Retrospective cohort of 72 Chinese patients (Fitzpatrick III–IV) treated with a 730-nm picosecond laser for ABNOM.
- Overall effectiveness rate was 75% after an average of 2.42 ± 0.75 sessions; progressive improvement across three sessions (p < .01).
- No hypopigmentation observed; postinflammatory hyperpigmentation occurred in 5.56%.
Methodological Strengths
- Blinded dermatologist assessments of high-resolution photographs using a standardized improvement scale
- Subgroup analysis demonstrating session-wise incremental benefit
Limitations
- Retrospective single-center design without a comparator group
- Population limited to Chinese patients; follow-up duration not detailed
Future Directions: Prospective controlled studies comparing wavelengths/devices, parameter optimization, and longer-term recurrence and dyspigmentation outcomes across skin types.
BACKGROUND: The effectiveness and safety of 730-nm picosecond laser for treating acquired bilateral nevus of Ota-like macules remain uncertain. OBJECTIVE: This study aims to evaluate the potential benefits and risks of using the 730-nm picosecond laser for ABNOM removal. METHODS: This is a retrospective review of patients who were presented to the clinic between January 2020 and January 2024 for the treatment of ABNOM with 730-nm picosecond laser alone. The efficacy of the laser was assessed based on the Quartile Improvement Scale, using high-resolution photographs evaluated by blinded dermatologists. RESULTS: A total of 72 Chinese participants with Fitzpatrick skin types III to IV were included in the study. The overall effective rate of the treatment was 75%, achieved after an average of 2.42 ± 0.75 sessions. A subgroup analysis of 41 patients who completed 3 treatment sessions showed statistically significant differences in outcomes across the sessions. The mean improvement scores for sessions 1, 2, and 3 were 1.63 ± 1.04, 2.66 ± 1.22, and 3.29 ± 1.17, respectively ( p < .01). No cases of hypopigmentation were observed. The incidence of postinflammatory hyperpigmentation was 5.56%. CONCLUSION: The 730-nm picosecond laser is a safe and effective treatment for ABNOM in Chinese patients.